Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2018

View Archived Issues

Kiss of death: tumor cells suck calcium from bone cells to metastasize

Data presented on BRM-inhibiting ureas as potential anticancer agents

Phase II trial explores whether EDP-1503 enhances response to pembrolizumab in advanced melanoma

PDE9 inhibition with CRD-733 shows promise for heart failure

SY-5609 selected for development from novel selective CDK7 inhibitor series

COQ8B acts as a modifier of thoracic aortic aneurysm severity

Microbiome-derived butyrate builds bone

Giving herpesviruses a TRIM

How malaria drugs fight cancer

Assembly Biosciences initiates first-in-human study of ABI-H2158

Promentis Pharmaceuticals completes phase I studies of SXC-2023

Hummingbird Bioscience presents unique mechanism of action for novel anti-HER3 antibody

FDA grants approval for Adcetris as first-line treatment for peripheral T-cell lymphoma

Promacta granted FDA approval for first-line SAA and breakthrough therapy designation for H-ARS

Japanese researchers patent compounds for fibrosis

Takeda Pharmaceutical presents CaS antagonists

FDA approves Aemcolo for the treatment of travelers' diarrhea

FDA approves IND for first-in-human study of GZ17-6.02

Chemotherapeutic agents reactivate HBV via ribophorin II downregulation

Bridge Biotherapeutics files IND for BBT-877

Bifunctional agent N-809 demonstrates effective cancer immunotherapeutic properties

First patient enrolled in a phase III study of clonidine micropellet for sciatica

First results presented with RNAi ARO-HBV in chronic HBV infection

First phase II data presented for IL-22 agonist F-652 in patients with alcoholic hepatitis

Proteostasis Therapeutics patents mutant CFTR correctors

Merck KGaA and Pfizer provide update on JAVELIN ovarian cancer program of avelumab

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...